For decades, the story of Alzheimer’s research has been dominated by a battle between amyloid-beta and tau amyloids, both of which can kill neurons and impact the brain’s abil ...

From theory to clinic, explore how molecular glue innovation is transforming targeted protein degradation for cancer and ...

Achieving good oral bioavailability for targeted protein degraders (TPDs) is vital in providing a patient-friendly way to ...

Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) ...

Panelists discuss recent phase 3 trials of novel endocrine agents in advanced breast cancer, highlighting benefits—especially ...

Dry brushing is a mechanical exfoliation technique using a stiff, natural-fiber brush on dry skin, promoted for improved circulation and lymphatic flow. However, scientific evidence supporting health ...

Healzen Therapeutics Co. Ltd. has patented new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase ...

Salarius also announces continued progress in its planned merger with Decoy Therapeutics Inc. (Decoy). Under the definitive agreement announced on January 13, 2025, Decoy will merge with a wholly ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

Constraining proximity-based drugs, such as proteolysis targeting chimeras (PROTACs), into their bioactive conformation can significantly impact their selectivity and potency. However, traditional ...

Proteolysis within the lipid bilayer is poorly understood, in particular the regulation of substrate cleavage. Rhomboids are a family of ubiquitous intramembrane serine proteases that harbour a buried ...